Japanese pharma major Takeda has entered into an agreement to divest a portfolio of select non-core prescription pharmaceutical products sold predominantly in Europe and Canada to Cheplapharm for $562 million. Cheplapharm is a specialty pharmaceutical company headquartered in Germany with a 25-year history of acquiring, integrating and growing pharmaceutical products.   The portfolio to be divested to Cheplapharm includes cardiovascular/metabolic and anti-inflammatory products along with calcium...